The Leukemia & Lymphoma Society Welcomes Five Members to Board of Directors
Retrieved on:
Monday, July 3, 2023
Carbon, Lymphoma, WCM, University, Moffitt, Gene, Dan, RYE, Pediatrics, Neoplasm, OpenText, Hodgkin lymphoma, Center for Cell and Gene Therapy, Bone marrow, Quality of life, Baylor University, National Cancer Institute, Medicine, Research, Houston Methodist Hospital, LLS, Accounting, Barrenechea, Wood, Mixed-phenotype acute leukemia, Doctor of Science, Ball, Texas Children's Hospital, Patient, Heel, Cell, Weill Cornell Medicine, Biology, Baylor College of Medicine, Hospital, Multiple myeloma, H. Lee Moffitt Cancer Center & Research Institute, FDA, 21st Critics' Choice Awards, Leukemia, III, Pharmacology, Management, Dentistry, Koppers
RYE BROOK, N.Y., July 3, 2023 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) announced five new members to its board of directors effective July 1, 2023: Leroy M. Ball, Mark J. Barrenechea, Helen E. Heslop, M.D., DSc (Hon), Ari Melnick, M.D., and Yvette Tremonti.
Key Points:
- RYE BROOK, N.Y., July 3, 2023 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) announced five new members to its board of directors effective July 1, 2023: Leroy M. Ball, Mark J. Barrenechea, Helen E. Heslop, M.D., DSc (Hon), Ari Melnick, M.D., and Yvette Tremonti.
- In his role, and with the dedication and commitment of LLS's Board of Directors, Dr. Kolb is leading the $500 million organization in its mission to cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life for blood cancer patients and their families.
- Leroy M. Ball: Leroy M. Ball is president and chief executive officer of Koppers and serves on the company's Board of Directors.
- Mark J. Barrenechea: Mark J. Barrenechea joined OpenText as president and chief executive officer in January 2012 and serves as a member of the Board of Directors.